These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 28882564)

  • 1. Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.
    Pomeroy JJ; Drusano GL; Rodriquez JL; Brown AN
    Antiviral Res; 2017 Oct; 146():149-152. PubMed ID: 28882564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
    Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
    Friborg J; Levine S; Chen C; Sheaffer AK; Chaniewski S; Voss S; Lemm JA; McPhee F
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1312-22. PubMed ID: 23274666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus.
    Chen M; Xu Y; Li N; Yin P; Zhou Q; Feng S; Wu T; Wei L; Wang H; Fu Y; Li YP
    J Gen Virol; 2021 Dec; 102(12):. PubMed ID: 34949310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.
    St Laurent DR; Serrano-Wu MH; Belema M; Ding M; Fang H; Gao M; Goodrich JT; Krause RG; Lemm JA; Liu M; Lopez OD; Nguyen VN; Nower PT; O'Boyle DR; Pearce BC; Romine JL; Valera L; Sun JH; Wang YK; Yang F; Yang X; Meanwell NA; Snyder LB
    J Med Chem; 2014 Mar; 57(5):1976-94. PubMed ID: 23573957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems.
    Camus G; Xu S; Han B; Lu J; Dvory-Sobol H; Yu M; Cheng G; Miller MD; Doehle BP; Mo H
    Virology; 2018 Jan; 514():134-141. PubMed ID: 29175627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.
    Wose Kinge CN; Espiritu C; Prabdial-Sing N; Sithebe NP; Saeed M; Rice CM
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5386-94. PubMed ID: 24982066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model.
    Mandour M; Vliegen I; Paeshuyse J; Neyts J
    Antiviral Res; 2018 Jan; 149():150-153. PubMed ID: 29154807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well.
    Mondal R; Koev G; Pilot-Matias T; He Y; Ng T; Kati W; Molla A
    Antiviral Res; 2009 Apr; 82(1):82-8. PubMed ID: 19174175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
    Lam AM; Murakami E; Espiritu C; Steuer HM; Niu C; Keilman M; Bao H; Zennou V; Bourne N; Julander JG; Morrey JD; Smee DF; Frick DN; Heck JA; Wang P; Nagarathnam D; Ross BS; Sofia MJ; Otto MJ; Furman PA
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3187-96. PubMed ID: 20516278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic Activity of Combined NS5A Inhibitors.
    O'Boyle DR; Nower PT; Gao M; Fridell R; Wang C; Hewawasam P; Lopez O; Tu Y; Meanwell NA; Belema M; Roberts SB; Cockett M; Sun JH
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1573-83. PubMed ID: 26711745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
    Frey A; Piras-Straub K; Walker A; Timm J; Gerken G; Herzer K
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29111569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B.
    Dufner-Beattie J; O'Guin A; O'Guin S; Briley A; Wang B; Balsarotti J; Roth R; Starkey G; Slomczynska U; Noueiry A; Olivo PD; Rice CM
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3399-410. PubMed ID: 24709254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of antiviral drug synergy in an infectious HCV system.
    Lin B; He S; Yim HJ; Liang TJ; Hu Z
    Antivir Ther; 2016; 21(7):595-603. PubMed ID: 27035622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
    Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient replication of a hepatitis C virus genotype 1b replicon chimera encoding NS5A-5B from genotype 3a.
    Kylefjord H; Danielsson A; Sedig S; Belda O; Wiktelius D; Vrang L; Targett-Adams P
    J Virol Methods; 2014 Jan; 195():156-63. PubMed ID: 24120570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes.
    Katsume A; Tokunaga Y; Hirata Y; Munakata T; Saito M; Hayashi H; Okamoto K; Ohmori Y; Kusanagi I; Fujiwara S; Tsukuda T; Aoki Y; Klumpp K; Tsukiyama-Kohara K; El-Gohary A; Sudoh M; Kohara M
    Gastroenterology; 2013 Oct; 145(4):865-73. PubMed ID: 23791700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
    Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.